Stopping Medicare payment for compounded drugs produced in violation of the FD&C Act would not be a reliable tool for addressing public safety issues associated with such products, the Centers for Medicare and Medicaid Services believe.
CMS said it disagreed with a recommendation by the HHS Office of the Inspector General that the Medicare program consider...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?